Jeffrey Rona

Introduction

Jeff Rona is an accomplished financial executive with significant experience in both the life sciences and financial services sectors. His career showcases a strong track record in venture capital, corporate development, business development, and financial operations. Jeff's journey began with a solid educational foundation, obtaining a Bachelor of Science in Accounting from Case Western Reserve University, where he studied from January 1986 to January 1990.

Professional Path

Jeff's professional path includes a series of impactful roles. Early on, he worked at Coopers & Lybrand as an Associate Director, offering corporate finance, tax, and accounting services. His career then expanded into the life sciences sector where he gained considerable experience and success.

Key Roles and Achievements

At Agenus, from July 1998 to April 2000, Jeff served as the Director of Finance and Acting CFO. During his tenure, he led a $72 million Initial Public Offering (IPO) and secured $53 million in venture capital, setting the company on a firm financial footing.

At UBS, from June 2000 to September 2002, he held the position of Director focusing on capital sourcing and strategic advice for hotel, gaming, and leisure companies.

At AlgoRx Pharmaceuticals, where he was the CFO from September 2002 to March 2006. In this role, he managed the company's merger with Corgentech and oversaw significant financing rounds.

At GlobeImmune, he served as Chief Business Officer from April 2006 to August 2011, leading major fundraising initiatives and strategic partnerships.

At Rona Capital, LLC, he led the firm as Managing Director between September 2011 and October 2014, providing advisory services to emerging companies.

At Great Basin Scientific, from October 2014 to October 2017, Jeff was instrumental as CFO in managing the company’s IPO and raising about $80 million in various financings, while also implementing SOX compliance.

At Danforth Advisors, as Managing Director for the West Region from October 2017 to October 2020, he focused on venture capital, life sciences, and equity capital markets.

At Ovid Therapeutics, most recently serving as Chief Business & Financial Officer since October 2020. In this capacity, Jeff has raised over $350 million in capital and led significant strategic transactions with major pharmaceutical companies.

Board Memberships

In addition to his professional roles, Jeff contributes his expertise as a Board Member at the Brooklyn Defenders and the S&W Seed Company Americas, where he also serves as the Audit Committee Chair.

Conclusion

Throughout his career, Jeff Rona has demonstrated exceptional skills in venture capital, public company financing, investor relations, mergers and acquisitions, and corporate development. His dedication and strategic vision have consistently led to significant achievements, making him a highly respected leader in his field.